Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
about
PI3K/AKT/mTOR Pathway in AngiogenesisPI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancerUpdates of mTOR inhibitorsInterferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapyDiscovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancerTargeting mTOR for the treatment of AML. New agents and new directionsTargeting the mTOR kinase domain: the second generation of mTOR inhibitorsPushing the envelope in the mTOR pathway: the second generation of inhibitorsAkt and autophagy cooperate to promote survival of drug-resistant gliomaThe PI3K pathway as drug target in human cancerNVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomasThe role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populationsLoss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancerPharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsPI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastomaDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting LKB1 in cancer - exposing and exploiting vulnerabilitiesTargeting p110gamma in gastrointestinal cancers: attack on multiple frontsGrowth factor and signaling pathways and their relevance to prostate cancer therapeuticsEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderPhosphatidylinositol 3-kinase and antiestrogen resistance in breast cancerNovel delivery strategies for glioblastomaEndothelial Rictor is crucial for midgestational development and sustained and extensive FGF2-induced neovascularization in the adult.Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivoTargeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesThe p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsGenetic and Pharmacological Inhibition of PDK1 in Cancer Cells: CHARACTERIZATION OF A SELECTIVE ALLOSTERIC KINASE INHIBITORA selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiationDiscovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of RapamycinDiscovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug DesignEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitorsConcomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Therapeutic targeting of cancers with loss of PTEN function.Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesIn vitro models of cancer stem cells and clinical applicationsmTOR inhibitors in cancer therapyAutophagy in thyroid cancer: present knowledge and future perspectivesChemical strategies for development of ATR inhibitorsPI3K/PTEN signaling in angiogenesis and tumorigenesis
P2860
Q21129332-98D5ABDF-561A-4094-BAE6-B842D453750CQ24338724-A71C8D2E-8949-4D9B-A781-B6541F0E59BDQ24607170-F3C060A2-0848-44BA-8705-DF4475B40CCEQ24611233-9B9C493F-6211-4AB2-98BF-CB7EBDFD2BEAQ24617184-3AEBEE6F-B66E-436F-8E65-864C2510988AQ24617223-7FF2E97A-EFC0-4F5D-8531-5183F04CC205Q24622194-7ED3369B-F92A-4911-9826-D780148D1B3AQ24622222-B775F474-268E-4EFE-B600-0B20DBB34D35Q24629677-7706FF3A-6192-422D-A449-5C4FA20B07D5Q24632283-FCB373A6-FE8E-4E8D-86FB-F1EED210EB4BQ24646237-CC7AF6FD-62B7-4F64-BA35-FBC85AC3970CQ24646816-CC9D3B90-1D4A-493F-92AD-B31423A61653Q24653934-4879182D-A279-4169-8467-774AB8FA1A4FQ26766292-0E943C49-BE89-49AE-8949-C0CB7ED2A95DQ26766293-1329D317-39D7-4145-B176-94BD2266020CQ26776513-0352C5FD-D9B9-4E48-85CC-73B13959C236Q26801412-7A5EBC75-6FEA-423F-8C75-CE9C73E89B1BQ26823575-FFC54282-034C-401E-B021-0B705F3694BEQ26827975-245FA32E-0680-4137-A024-6A7F0DD32569Q26859114-773A546F-05B3-45D4-A629-E678B507CE34Q26862550-D19269FD-9DC3-49E0-98AE-59FEA13DD6A9Q27006099-23CFDB09-09D7-4534-B40C-76E65AC5A1BCQ27304564-18D7C4D6-1600-47A6-ACDB-61A7040D7B8BQ27644291-F575DC51-8693-402F-83C4-C59EB168B730Q27652488-2FBDE6D5-6377-41A4-9AAF-585760A024FEQ27659013-70A2D93C-9F3A-4706-A47A-34AC585C0145Q27666122-F467C8AE-EA18-4D4D-9A00-9B4E150BE757Q27678799-48DDA89E-DDAF-47B4-8E0B-71056940A97EQ27684091-CDA9C2FA-5EDE-4D54-ADD9-6AD3B8152B19Q27684163-C98D8E52-5EE4-4D66-96B5-1A359FAE82EAQ27851457-C07AD0F4-6B66-4209-9C11-4AD896FF1F1FQ27851975-4589D155-1008-4850-BF7E-4599994F3AF9Q27852136-7119316D-42B0-457E-9DDC-F69B90A42BF2Q27852764-72D2457A-4A38-424D-A43E-55C3F94E4E24Q28071388-16B2C00B-F4EB-44EE-BBE6-88132D5D54C6Q28076101-3BF637AC-C316-4BB2-B80C-105E94090D21Q28079129-5E355CEE-91A5-4C20-B5C9-DD1586FBCF01Q28086785-E1D41DF0-9B0E-484D-9E13-B33D6F96085FQ28239738-5F7EB8CB-A02E-475C-8FD7-276276E8FC9FQ28383083-B30E812C-93CC-494F-AB34-35A083B516CD
P2860
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
description
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
im Juli 2008 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: July 2008)
@en
wetenschappelijk artikel (gepubliceerd in 2008-07)
@nl
наукова стаття, опублікована в липні 2008
@uk
مقالة علمية (نشرت في يوليو 2008)
@ar
name
Identification and characteriz ...... ent in vivo antitumor activity
@ast
Identification and characteriz ...... ent in vivo antitumor activity
@en
type
label
Identification and characteriz ...... ent in vivo antitumor activity
@ast
Identification and characteriz ...... ent in vivo antitumor activity
@en
prefLabel
Identification and characteriz ...... ent in vivo antitumor activity
@ast
Identification and characteriz ...... ent in vivo antitumor activity
@en
P2093
P3181
P1476
Identification and characteriz ...... ent in vivo antitumor activity
@en
P2093
Brachmann S
Brueggen J
De Pover A
García-Echeverría C
P304
P3181
P356
10.1158/1535-7163.MCT-08-0017
P407
P577
2008-07-01T00:00:00Z